Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Mar-Apr;31(2):521-523.
doi: 10.4103/1319-2442.284029.

Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide

Umesh Lingaraj  1 , Kishan Aralapuram  1 , Sreedhara Chikkanayakanhalli  1 , Akila Vishwanathan  1 , Mahesha Vankalakunti  2
Affiliations
Case Reports

Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide

Umesh Lingaraj et al. Saudi J Kidney Dis Transpl. 2020 Mar-Apr.

Abstract

Recurrence of glomerulonephritis is the third-leading cause of allograft loss. Graft loss due to IgA nephropathy occurs in 10% at 10-year follow-up. The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation with favorable safety profile. We are reporting a case of successful treatment of a patient with posttransplant IgA nephropathy with TRF of budesonide.

PubMed Disclaimer

Publication types

LinkOut - more resources